Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shengu Capsule for Postmenopausal Osteoporosis (Liver–Kidney Deficiency) – Randomized Controlled Multicentre Trial
ChiCTR2100047971Phase 4Not yet recruiting
- Sponsor
- Fujian Academy of Chinese Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Shengu Capsule in postmenopausal osteoporosis (2 arms), sponsored by Fujian Academy of Chinese Medical Sciences. Primary endpoints: Visual Analog Scale (VAS) score, Alkaline phosphatase (ALP) and 3 more. Planned start May 2021; status: not yet recruiting.
02
Drugs
Shengu Capsule
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on ChiCTR2100047971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047971.